Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
W-OVA1
- Development stage
- Unknown
- Lead developer
- University Medical Center Groningen
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intranodal
01
Overview
W-OVA1 is an investigational mRNA-based cancer vaccine developed by the University Medical Center Groningen (UMCG) for the treatment of primary ovarian cancer. The vaccine consists of messenger RNA (mRNA) encoding the Wilms' Tumor 1 (WT1) protein, a well-characterized tumor-associated antigen that is highly expressed in ovarian malignancies. Upon administration via intranodal injection, the mRNA is taken up by dendritic cells, which then present WT1 epitopes to the immune system, stimulating a targeted T-cell response against WT1-expressing tumor cells. In the Phase I OLIVIA clinical trial, W-OVA1 is evaluated in combination with neoadjuvant chemotherapy (carboplatin and paclitaxel) to assess safety and immunogenicity in patients with advanced-stage ovarian cancer.
- Other names
- W_ova1 mRNA vaccineWT1 mRNA vaccineWT-1 mRNA vaccineWT 1 mRNA vaccineOLIVIA vaccine
02
Targets
WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on W-OVA1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on W-OVA1.